Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more
Market Cap & Net Worth: Wockhardt Limited (WOCKPHARMA)
Wockhardt Limited (NSE:WOCKPHARMA) has a market capitalization of $2.23 Billion (₹193.15 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #7129 globally and #259 in its home market, demonstrating a -8.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wockhardt Limited's stock price ₹1188.70 by its total outstanding shares 162492169 (162.49 Million).
Wockhardt Limited Market Cap History: 2015 to 2026
Wockhardt Limited's market capitalization history from 2015 to 2026. Data shows change from $2.61 Billion to $2.23 Billion (-1.77% CAGR).
Index Memberships
Wockhardt Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$68.11 Billion | 1.54% | #7 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.08% | #237 of 750 |
Weight: Wockhardt Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Wockhardt Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wockhardt Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Wockhardt Limited's market cap is 0.09 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.14 Billion | $44.53 Billion | $2.51 Billion | 0.03x | 0.45x |
| 2017 | $1.61 Billion | $39.66 Billion | -$1.96 Billion | 0.04x | N/A |
| 2018 | $905.02 Million | $39.24 Billion | -$6.08 Billion | 0.02x | N/A |
| 2019 | $404.64 Million | $35.66 Billion | -$1.95 Billion | 0.01x | N/A |
| 2020 | $945.32 Million | $28.44 Billion | -$692.20 Million | 0.03x | N/A |
| 2021 | $714.07 Million | $27.08 Billion | $6.86 Billion | 0.03x | 0.10x |
| 2022 | $418.50 Million | $32.30 Billion | -$2.44 Billion | 0.01x | N/A |
| 2023 | $796.20 Million | $26.57 Billion | -$5.59 Billion | 0.03x | N/A |
| 2024 | $2.66 Billion | $28.30 Billion | -$4.63 Billion | 0.09x | N/A |
| 2025 | $2.71 Billion | $30.35 Billion | -$470.00 Million | 0.09x | N/A |
Competitor Companies of WOCKPHARMA by Market Capitalization
Companies near Wockhardt Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Wockhardt Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Wockhardt Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Wockhardt Limited's market cap moved from $2.61 Billion to $ 2.23 Billion, with a yearly change of -1.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹2.23 Billion | -17.81% |
| 2025 | ₹2.71 Billion | +2.07% |
| 2024 | ₹2.66 Billion | +233.89% |
| 2023 | ₹796.20 Million | +90.25% |
| 2022 | ₹418.50 Million | -41.39% |
| 2021 | ₹714.07 Million | -24.46% |
| 2020 | ₹945.32 Million | +133.62% |
| 2019 | ₹404.64 Million | -55.29% |
| 2018 | ₹905.02 Million | -43.82% |
| 2017 | ₹1.61 Billion | +41.60% |
| 2016 | ₹1.14 Billion | -56.38% |
| 2015 | ₹2.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Wockhardt Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.23 Billion USD |
| MoneyControl | $2.23 Billion USD |
| MarketWatch | $2.23 Billion USD |
| marketcap.company | $2.23 Billion USD |
| Reuters | $2.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.